Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Growth in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 77,000 shares, a growth of 40.8% from the October 31st total of 54,700 shares. Based on an average daily volume of 337,300 shares, the days-to-cover ratio is currently 0.2 days. Approximately 5.8% of the company’s shares are short sold.

Sonoma Pharmaceuticals Stock Performance

NASDAQ:SNOA remained flat at $2.79 during trading hours on Friday. 36,732 shares of the company’s stock traded hands, compared to its average volume of 201,845. The firm has a 50 day moving average price of $2.90 and a 200 day moving average price of $1.54. The stock has a market cap of $3.74 million, a P/E ratio of -0.56 and a beta of 1.38. Sonoma Pharmaceuticals has a 1 year low of $2.52 and a 1 year high of $9.37.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 1.95% of the stock is owned by institutional investors and hedge funds.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.